Unresectable Pancreatic Adenocarcinoma Clinical Trials

12 clinical trials for Unresectable Pancreatic Adenocarcinoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene — RECRUITING · PHASE1
• TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma — RECRUITING · PHASE1
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations — RECRUITING · PHASE3
• LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia — RECRUITING
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy — ACTIVE_NOT_RECRUITING · NA
• Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma — WITHDRAWN · PHASE2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients — COMPLETED

Refine this search